Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis

Giannini, Edoardo G.; Borro, Paolo; Botta, Federica; Fumagalli, Alessandra; Malfatti, Federica; Podestá, Elena; Romagnoli, Paola; Testa, Emanuela; Chiarbonello, Bruno; Polegato, Simone; Mamone, Mario; Testa, Roberto

doi:10.1016/s0168-8278(02)00274-x

Cited by 100 publications

(94 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Impaired production of thrombopoietin may develop after long-term hepatic necrosis and advanced fibrosis in patients with chronic HCV infection, leading to impaired platelet production. 30,31 The results of our pilot studies agree with earlier researchers' observations. Mean platelet counts decreased in relation to both increased pathologic fibrotic scores and US parenchyma scores among patients with chronic HCV infection.…”

Section: Discussionsupporting

confidence: 92%

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma

Wang

Liu

et al. 2006

Cancer

148

131

View full text Add to dashboard Cite

BACKGROUND.The objective of this study was to examine the usefulness of platelet counts in the diagnosis of cirrhosis and for identifying high‐risk individuals in a community‐based hepatocellular carcinoma (HCC) screening program.METHODS.Pilot Study 1 determined the correlation between platelet counts and pathologic hepatic fibrosis scores among individuals with chronic hepatitis B virus (HBV) infection (n = 122 patients) and hepatitis C virus (HCV) infection (n = 244 patients). Pilot Study 2 investigated proportions of individuals with thrombocytopenia (<150 × 103/mm3) among patients with HCC (n = 4042 patients). Pilot Study 3 demonstrated the correlation between platelet counts and ultrasonographic (US) parenchyma scores among anti‐HCV‐positive individuals (n = 75 patients). The core study was a 2‐stage, community‐based screening for HCC among residents age 40 years or older in townships with a high prevalence of anti‐HCV (n = 4616 individuals) and in townships with a low prevalence of anti‐HCV (n = 1694 individuals). Patients with thrombocytopenia were identified for US and α‐fetoprotein screening.RESULTS.Among the individuals who were positive for anti‐HCV, platelet counts decreased according to increased pathologic fibrosis scores or US scores for liver parenchyma disease: The best cutoff platelet count was 150 × 103/mm3 for a diagnosis of cirrhosis. The sensitivity and specificity were 68.2% and 76.4%, respectively, for pathologic cirrhosis and 76.2% and 87.8%, respectively, for US cirrhosis. Forty‐eight percent of patients with HCC were thrombocytopenic. The proportion of thrombocytopenia was significantly greater in patients with HCV‐related HCC (63%) than in patients with HBV‐related HCC (42%). In the townships with high and low anti‐HCV prevalence, the prevalence of thrombocytopenia was 17.9% and 6.1%, respectively, (P < .001), respectively. Twenty‐five patients were diagnosed with HCC, and all of those patients resided in the high‐prevalence township.CONCLUSIONS.Thrombocytopenia was a valid surrogate of cirrhosis and a valid marker for the identification of individuals at high‐risk for HCC, especially in areas that had a high prevalence of HCV. Cancer 2006. © 2006 American Cancer Society.

show abstract

Section: Discussionsupporting

confidence: 92%

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma

Wang

Liu

et al. 2006

Cancer

148

131

View full text Add to dashboard Cite

show abstract

“…Thrombocytopenia occurs in up to 64% of cirrhotic patients (Bashour et al 2000). Patients with advanced end-stage liver disease tend to have a higher degree of thrombocytopenia than those patients with compensated cirrhosis (Adinolfi et al 2001;Giannini et al 2002). Patients with thrombocytopenia are sometimes unable to receive antiviral therapy with a sufficiently high dose of interferon (IFN) to treat hepatitis virus infection or are unable to undergo curative surgery for hepatocellular carcinoma (HCC).…”

Section: Introductionmentioning

confidence: 99%

Platelet Transfusion Improves Liver Function in Patients with Chronic Liver Disease and Cirrhosis

Maruyama

Murata

Takahashi

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…Table 4 shows also that no statistically significant changes or differences in biochemical parameters after Danazol treatment and after 3 months follow up except significant decrease of serum albumin only after treatment. Table ( 5) shows that the patients younger than 50 years and females had a significantly higher probability of achieving response to…”

Section: Resultsmentioning

confidence: 99%

“…Patients with HCV seem to develop lower platelet levels than patients with other causes of cirrhosis due to bone marrow suppression either by HCV directly, or immune-mediated platelet destruction involving anti-platelet antibodies and/or immune complex associated platelet clearance [2,3] and impaired thrombopoietin production or activity resulting from hepatocellular damage [4,5].…”

Section: Introductionmentioning

confidence: 99%

Danazol one Month Treatment of Thrombocytopenia in Chronic Hepatitis C

Dawod¹,

Monem²

2016

Med-Science

View full text Add to dashboard Cite

show abstract

Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis

Cited by 100 publications

References 27 publications

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma

Platelet Transfusion Improves Liver Function in Patients with Chronic Liver Disease and Cirrhosis

Danazol one Month Treatment of Thrombocytopenia in Chronic Hepatitis C

Contact Info

Product

Resources

About